First participant dosed with Neurizon’s lead drug candidate in landmark HEALEY ALS trial

The first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon Therapeutics’ lead ...

Axon Neuroscience’s Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...
Rolling Out

Failed ALS trials reveal major medical breakthrough

When the results of the first-ever platform trial for amyotrophic lateral sclerosis (ALS) were published this February, the headlines might have seemed disappointing: four experimental drugs failed to ...
Morningstar

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance ...

Investor-focused update underscores enrollment momentum, biomarker strategy, and near-term data readouts designed to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS SEATTLE ...